Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) is a publicly traded Healthcare sector company. As of November 9, 2026, EPRX trades at $7.11 with a market cap of $455.25M and a P/E ratio of 0.00. EPRX moved +3.21% today. Year to date, EPRX is -8.98%; over the trailing twelve months it is +23.59%. Its 52-week range spans $2.68 to $9.32. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces EPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eupraxia to present new RESOLVE Phase 1b/2 EP-104GI data at ACG, UEG meetings: Eupraxia said updated analyses from its RESOLVE trial of EP-104GI in eosinophilic esophagitis will be presented at ACG on Oct. 12, 2026, and UEG on Oct. 18-19; interim Phase 2b data are expected in December 2026.
| Metric | Value |
|---|---|
| Price | $7.11 |
| Market Cap | $455.25M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.32 |
| 52-Week Low | $2.68 |
| Volume | 51 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
8 analysts cover EPRX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.